BioNTech stock draws Moderate Buy consensus at USD 126 target
Published on 10/05/2026 at 18:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
BioNTech stock (ISIN US09075V1026) was trading at USD 97.10 on Nasdaq at 12:25 p.m. ET on October 5, 2026, up 0.20 percent. MarketBeat reported a Moderate Buy consensus from 19 brokerages, giving the stock a defined analyst benchmark despite the modest intraday move.
Analysts set USD 126 benchmark
The consensus includes 12 Buy ratings, five Holds, one Sell rating and one Strong Buy rating, according to MarketBeat on October 3, 2026. Its average 12-month price target is USD 126, which places the price target 29.7 percent above the Nasdaq price of USD 97.10.
The range of views is wide. Yahoo Finance reported on September 16, 2026, that Berenberg raised its target from USD 132 to USD 140 while keeping a Buy rating.
Quarterly loss tests the pipeline
The valuation debate is set against a difficult operating quarter. For the quarter ended June 30, BioNTech reported USD 105.6 million in revenue and a USD 820.8 million GAAP net loss, compared with USD 260.8 million in revenue and a USD 386.6 million loss a year earlier, according to The Globe and Mail on October 2, 2026.
That contrast leaves BioNTech dependent on progress across its oncology pipeline while COVID-19 vaccine demand contributes less revenue. Investing.com reported on September 16, 2026, that UBS maintained a Buy rating and a USD 135 target after lung cancer data, including median overall survival of 18.5 months versus 10.0 months for docetaxel in a trial stage.
Stock remains below yearly high
BioNTech's Nasdaq market capitalization stood at USD 24.4 billion on October 5, 2026, with volume of 308,349 shares. The 52-week range was USD 79.52 to USD 124.00, leaving the stock USD 26.90 below its yearly high.
For investors, the central tension is visible in the numbers: the analyst target points to a higher valuation, while the June quarter shows a wider GAAP loss and lower revenue than a year earlier.
Nasdaq price and market value
BioNTech stock was last at USD 97.10 on Nasdaq on October 5, 2026, at 12:25 p.m. ET, with a market capitalization of USD 24.4 billion.
BioNTech stock key data
- Company: BioNTech SE
- ISIN: US09075V1026
- Ticker: BNTX
- Trading venue: Nasdaq
- Price (as of October 5, 2026, 12:25 p.m. ET): USD 97.10
- Market capitalization: USD 24.4 billion (as of October 5, 2026)
- 52-week range: USD 79.52-124.00 (as of October 5, 2026)
- Sector / Industry: Health Care / Biotechnology and Medical Research
